JP2017214384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017214384A5 JP2017214384A5 JP2017112578A JP2017112578A JP2017214384A5 JP 2017214384 A5 JP2017214384 A5 JP 2017214384A5 JP 2017112578 A JP2017112578 A JP 2017112578A JP 2017112578 A JP2017112578 A JP 2017112578A JP 2017214384 A5 JP2017214384 A5 JP 2017214384A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pharmaceutical composition
- composition according
- pancreatic
- stro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims description 21
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 230000004064 dysfunction Effects 0.000 claims 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000007423 decrease Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 210000000496 pancreas Anatomy 0.000 claims 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 3
- 102000051325 Glucagon Human genes 0.000 claims 3
- 108060003199 Glucagon Proteins 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 208000020450 carbohydrate metabolism disease Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 3
- 229960004666 glucagon Drugs 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 102100025683 Alkaline phosphatase, tissue-nonspecific isozyme Human genes 0.000 claims 2
- 239000004382 Amylase Substances 0.000 claims 2
- 102000013142 Amylases Human genes 0.000 claims 2
- 108010065511 Amylases Proteins 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 101000574445 Homo sapiens Alkaline phosphatase, tissue-nonspecific isozyme Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 235000019418 amylase Nutrition 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 208000017745 inborn carbohydrate metabolic disease Diseases 0.000 claims 2
- 210000004153 islets of langerhan Anatomy 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000002571 pancreatic alpha cell Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims 1
- 208000010444 Acidosis Diseases 0.000 claims 1
- 102000005367 Carboxypeptidases Human genes 0.000 claims 1
- 108010006303 Carboxypeptidases Proteins 0.000 claims 1
- 108010038061 Chymotrypsinogen Proteins 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000035197 Disorder of carbohydrate metabolism Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010072104 Fructose intolerance Diseases 0.000 claims 1
- 208000027472 Galactosemias Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010019878 Hereditary fructose intolerance Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010070070 Hypoinsulinaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000007976 Ketosis Diseases 0.000 claims 1
- 208000006136 Leigh Disease Diseases 0.000 claims 1
- 208000017507 Leigh syndrome Diseases 0.000 claims 1
- 206010025476 Malabsorption Diseases 0.000 claims 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims 1
- 206010027417 Metabolic acidosis Diseases 0.000 claims 1
- 208000008955 Mucolipidoses Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims 1
- 102000016387 Pancreatic elastase Human genes 0.000 claims 1
- 108010067372 Pancreatic elastase Proteins 0.000 claims 1
- 102000019280 Pancreatic lipases Human genes 0.000 claims 1
- 108050006759 Pancreatic lipases Proteins 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims 1
- 102000018690 Trypsinogen Human genes 0.000 claims 1
- 108010027252 Trypsinogen Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- WQZGKKKJIJFFOK-PQMKYFCFSA-N alpha-D-mannose Chemical compound OC[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-PQMKYFCFSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000027746 artery morphogenesis Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- WQZGKKKJIJFFOK-RWOPYEJCSA-N beta-D-mannose Chemical compound OC[C@H]1O[C@@H](O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-RWOPYEJCSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000035860 hypoinsulinemia Effects 0.000 claims 1
- 230000004140 ketosis Effects 0.000 claims 1
- 201000007769 mucolipidosis Diseases 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 230000003282 necrolytic effect Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 208000030212 nutrition disease Diseases 0.000 claims 1
- 208000019180 nutritional disease Diseases 0.000 claims 1
- 230000010003 pancreatic endocrine function Effects 0.000 claims 1
- 230000004203 pancreatic function Effects 0.000 claims 1
- 229940116369 pancreatic lipase Drugs 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000005167 vascular cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19979608P | 2008-11-20 | 2008-11-20 | |
| US61/199,796 | 2008-11-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015111995A Division JP6499016B2 (ja) | 2008-11-20 | 2015-06-02 | 膵機能障害の治療または予防方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162845A Division JP7051770B2 (ja) | 2008-11-20 | 2019-09-06 | 膵機能障害の治療または予防方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017214384A JP2017214384A (ja) | 2017-12-07 |
| JP2017214384A5 true JP2017214384A5 (OSRAM) | 2019-02-21 |
Family
ID=42197754
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536703A Active JP5891034B2 (ja) | 2008-11-20 | 2009-11-19 | 膵機能障害の治療または予防方法 |
| JP2015111995A Active JP6499016B2 (ja) | 2008-11-20 | 2015-06-02 | 膵機能障害の治療または予防方法 |
| JP2017112578A Withdrawn JP2017214384A (ja) | 2008-11-20 | 2017-06-07 | 膵機能障害の治療または予防方法 |
| JP2019162845A Active JP7051770B2 (ja) | 2008-11-20 | 2019-09-06 | 膵機能障害の治療または予防方法 |
| JP2021177234A Withdrawn JP2022031662A (ja) | 2008-11-20 | 2021-10-29 | 膵機能障害の治療または予防方法 |
| JP2023086994A Active JP7751607B2 (ja) | 2008-11-20 | 2023-05-26 | 膵機能障害の治療または予防方法 |
| JP2025099335A Pending JP2025148353A (ja) | 2008-11-20 | 2025-06-13 | 膵機能障害の治療または予防方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011536703A Active JP5891034B2 (ja) | 2008-11-20 | 2009-11-19 | 膵機能障害の治療または予防方法 |
| JP2015111995A Active JP6499016B2 (ja) | 2008-11-20 | 2015-06-02 | 膵機能障害の治療または予防方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162845A Active JP7051770B2 (ja) | 2008-11-20 | 2019-09-06 | 膵機能障害の治療または予防方法 |
| JP2021177234A Withdrawn JP2022031662A (ja) | 2008-11-20 | 2021-10-29 | 膵機能障害の治療または予防方法 |
| JP2023086994A Active JP7751607B2 (ja) | 2008-11-20 | 2023-05-26 | 膵機能障害の治療または予防方法 |
| JP2025099335A Pending JP2025148353A (ja) | 2008-11-20 | 2025-06-13 | 膵機能障害の治療または予防方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8894972B2 (OSRAM) |
| EP (2) | EP2350266B1 (OSRAM) |
| JP (7) | JP5891034B2 (OSRAM) |
| KR (2) | KR101832497B1 (OSRAM) |
| CN (3) | CN103800370B (OSRAM) |
| AU (1) | AU2009317874B2 (OSRAM) |
| CA (1) | CA2744228C (OSRAM) |
| DK (1) | DK2350266T3 (OSRAM) |
| ES (2) | ES2550795T3 (OSRAM) |
| WO (1) | WO2010057260A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008006168A1 (en) * | 2006-07-12 | 2008-01-17 | Angioblast Systems, Inc. | Treatment of excessive neovascularization |
| US8894972B2 (en) | 2008-11-20 | 2014-11-25 | Mesoblast, Inc. | Method for treating or preventing a pancreatic dysfunction |
| JP5984396B2 (ja) | 2009-03-05 | 2016-09-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 分泌されたａＰ２およびこれを阻害する方法 |
| EP2593115A4 (en) | 2010-07-02 | 2013-12-04 | Mesoblast Inc | Treatment of t-cell mediated immune disorders |
| CN107638428B (zh) * | 2011-05-19 | 2021-07-23 | 麦瑟布莱斯特公司 | 用于治疗肥胖症和/或代谢综合征的方法 |
| CN109276706A (zh) | 2011-06-03 | 2019-01-29 | 麦瑟布莱斯特公司 | 治疗或预防神经性疾病的方法 |
| ES3013463T3 (en) * | 2011-07-04 | 2025-04-14 | Mesoblast Inc | Treating or preventing rheumatic disease |
| ES2675693T3 (es) | 2011-07-06 | 2018-07-11 | Cell Therapy Limited | Células progenitoras de linaje mesodérmico |
| CN104098682B (zh) * | 2013-04-03 | 2018-01-02 | 苏州偲聚生物材料有限公司 | 多肽、包含该多肽的检测器件和检测试剂盒 |
| SG10201705061RA (en) * | 2012-12-12 | 2017-07-28 | Mesoblast Inc | Treatment of Diseases of Endothelial Dysfunction and Inflammation |
| US20140314872A1 (en) * | 2013-04-22 | 2014-10-23 | Hans Klingemann | Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction |
| CN104714021B (zh) * | 2013-12-12 | 2016-05-25 | 张曼 | 尿液凝血酶原蛋白在2型糖尿病合并冠心病中的应用 |
| BR112017023158A2 (pt) | 2015-04-30 | 2018-07-24 | Harvard College | anticorpos anti-ap2 e agentes de ligação de antígeno para tratar distúrbios metabólicos |
| JP7038707B2 (ja) * | 2016-06-27 | 2022-03-18 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 代謝障害の治療に有用な化合物 |
| CA3066733A1 (en) | 2017-06-09 | 2018-12-13 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
| CN110959579A (zh) * | 2019-11-14 | 2020-04-07 | 顾隽 | 患者来源的淋巴瘤免疫缺陷小鼠移植瘤模型的构建方法及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DK0648271T3 (da) | 1991-08-20 | 2003-07-21 | Us Gov Health & Human Serv | Adenovirusmedieret overførsel af gener til mave-/tarmkanal |
| AU2003901668A0 (en) | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
| AUPQ147799A0 (en) | 1999-07-07 | 1999-07-29 | Medvet Science Pty. Ltd. | Mesenchymal precursor cell |
| DE19939781C2 (de) | 1999-08-21 | 2003-06-18 | Schott Glas | Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken |
| AU2003262628A1 (en) * | 2002-08-14 | 2004-03-03 | University Of Florida | Bone marrow cell differentiation |
| KR100821128B1 (ko) * | 2003-11-04 | 2008-04-14 | 가부시키가이샤 바이오마스타 | 지방 조직으로부터 줄기세포를 생성하는 방법 및 시스템 |
| KR101536613B1 (ko) * | 2004-09-24 | 2015-07-14 | 메소블라스트, 아이엔씨. | 증폭된 다능성 간엽 전구세포 자손 및 이의 용도 |
| KR101446634B1 (ko) * | 2005-04-12 | 2014-10-16 | 메소블라스트, 아이엔씨. | 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체세포의 분리 |
| GB0514785D0 (en) * | 2005-07-19 | 2005-08-24 | Innovia Films Ltd | Sealed ream wrap package and films suitable for forming such packages |
| US20120027729A1 (en) * | 2006-04-28 | 2012-02-02 | Tulane University Health Sciences Center | Methods for treating diabetes |
| AU2008210988B2 (en) * | 2007-02-01 | 2012-09-06 | Allocure, Inc. | Potentiation of stem cell homing and treatment of organ dysfunction or organ failure |
| US8894972B2 (en) * | 2008-11-20 | 2014-11-25 | Mesoblast, Inc. | Method for treating or preventing a pancreatic dysfunction |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
-
2009
- 2009-11-19 US US13/129,180 patent/US8894972B2/en active Active
- 2009-11-19 ES ES09827049.9T patent/ES2550795T3/es active Active
- 2009-11-19 KR KR1020117012519A patent/KR101832497B1/ko active Active
- 2009-11-19 WO PCT/AU2009/001511 patent/WO2010057260A1/en not_active Ceased
- 2009-11-19 ES ES15178550.8T patent/ES2651503T3/es active Active
- 2009-11-19 EP EP09827049.9A patent/EP2350266B1/en active Active
- 2009-11-19 CN CN201310652234.XA patent/CN103800370B/zh active Active
- 2009-11-19 CA CA2744228A patent/CA2744228C/en active Active
- 2009-11-19 KR KR1020187004814A patent/KR102011609B1/ko active Active
- 2009-11-19 EP EP15178550.8A patent/EP3002329B1/en active Active
- 2009-11-19 CN CN201410727242.0A patent/CN104546912B/zh active Active
- 2009-11-19 DK DK09827049.9T patent/DK2350266T3/en active
- 2009-11-19 CN CN200980155054.2A patent/CN102307992B/zh active Active
- 2009-11-19 JP JP2011536703A patent/JP5891034B2/ja active Active
- 2009-11-19 AU AU2009317874A patent/AU2009317874B2/en active Active
-
2014
- 2014-11-07 US US14/535,827 patent/US9480713B2/en active Active
-
2015
- 2015-06-02 JP JP2015111995A patent/JP6499016B2/ja active Active
-
2016
- 2016-10-27 US US15/336,234 patent/US9968640B2/en active Active
-
2017
- 2017-06-07 JP JP2017112578A patent/JP2017214384A/ja not_active Withdrawn
-
2019
- 2019-09-06 JP JP2019162845A patent/JP7051770B2/ja active Active
-
2021
- 2021-10-29 JP JP2021177234A patent/JP2022031662A/ja not_active Withdrawn
-
2023
- 2023-05-26 JP JP2023086994A patent/JP7751607B2/ja active Active
-
2025
- 2025-06-13 JP JP2025099335A patent/JP2025148353A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017214384A5 (OSRAM) | ||
| JP2012509283A5 (OSRAM) | ||
| Oshima et al. | Differential myocardial infarct repair with muscle stem cells compared to myoblasts | |
| JP7751607B2 (ja) | 膵機能障害の治療または予防方法 | |
| Tan et al. | Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention | |
| List et al. | Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells | |
| Halban et al. | Gene and cell-replacement therapy in the treatment of type 1 diabetes: how high must the standards be set? | |
| Cani et al. | Involvement of endogenous glucagon-like peptide-1 (7–36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats | |
| Migliorini et al. | Islet cell plasticity and regeneration | |
| Pandey et al. | Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective | |
| JP2022031662A5 (OSRAM) | ||
| EP2627770B1 (en) | Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders | |
| Takahashi et al. | Regenerative and transplantation medicine: cellular therapy using adipose tissue-derived mesenchymal stromal cells for type 1 diabetes mellitus | |
| JP2015205894A5 (OSRAM) | ||
| Longo et al. | Glycemic control and the heart: the tale of diabetic cardiomyopathy continues | |
| CN106279400A (zh) | P8降糖肽的设计及其用途 | |
| JP2020502140A5 (OSRAM) | ||
| JP2020502151A5 (OSRAM) | ||
| Salvatore et al. | Incretin hormones: the link between glycemic index and cardiometabolic diseases | |
| Mu-U-Min et al. | Immune Evasion in Stem Cell-Based Diabetes Therapy—Current Strategies and Their Application in Clinical Trials | |
| Dezashibi et al. | A Mini-review of Current Treatment approaches and Gene Therapy as potential interventions for diabetes Mellitus types 1 | |
| US20200046700A1 (en) | Focal adhesion kinase inhibitor as a therapeutic agent in diabetes | |
| Hammerman | Xenotransplantation of embryonic pig pancreas for treatment of diabetes mellitus in non-human primates | |
| Patra et al. | Next-generation therapies for type 2 diabetes mellitus | |
| Kuwar et al. | Stem Cells: An Exciting Avenue for Diabetes Mellitus. |